Literature DB >> 22658484

Prolactin promotes mammary pathogenesis independently from cyclin D1.

Jennifer M Asher1, Kathleen A O'Leary, Debra E Rugowski, Lisa M Arendt, Linda A Schuler.   

Abstract

Epidemiological and experimental studies have revealed an important role for prolactin (PRL) in breast cancer. Cyclin D1 is a major downstream target of PRL in lobuloalveolar development during pregnancy and is amplified and/or overexpressed in many breast carcinomas. To examine the importance of cyclin D1 in PRL-induced pathogenesis, we generated transgenic mice (NRL-PRL) that overexpress PRL in mammary epithelial cells, with wild-type, heterozygous, or genetically ablated cyclin D1 in the FVB/N genetic background. Although loss of one cyclin D1 allele did not affect PRL-induced mammary lesions in nonparous females, the complete absence of cyclin D1 (D1(-/-)) markedly decreased tumor incidence. Nevertheless, NRL-PRL/D1(-/-) females developed significantly more preneoplastic lesions (eg, epithelial hyperplasias and mammary intraepithelial neoplasias) than D1(-/-) females. Moreover, although lack of cyclin D1 reduced proliferation of morphologically normal mammary epithelium, transgenic PRL restored it to rates of wild-type females. PRL posttranscriptionally increased nuclear cyclin D3 protein in D1(-/-) luminal cells, indicating one compensatory mechanism. Consistently, pregnancy induced extensive lobuloalveolar growth in the absence of cyclin D1. However, transcripts for milk proteins were reduced, and pups failed to survive, suggesting that mammary differentiation was inadequate. Together, these results indicate that cyclin D1 is an important, but not essential, mediator of PRL-induced mammary proliferation and pathology in FVB/N mice and is critical for differentiation and lactation.
Copyright © 2012 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22658484      PMCID: PMC3388158          DOI: 10.1016/j.ajpath.2012.03.041

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  53 in total

Review 1.  The cyclins and cyclin-dependent kinase inhibitors in hormonal regulation of proliferation and differentiation.

Authors:  R G Pestell; C Albanese; A T Reutens; J E Segall; R J Lee; A Arnold
Journal:  Endocr Rev       Date:  1999-08       Impact factor: 19.871

2.  Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4.

Authors:  E Neuman; M H Ladha; N Lin; T M Upton; S J Miller; J DiRenzo; R G Pestell; P W Hinds; S F Dowdy; M Brown; M E Ewen
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

3.  Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis.

Authors:  Mark W Landis; Basil S Pawlyk; Tiansen Li; Piotr Sicinski; Philip W Hinds
Journal:  Cancer Cell       Date:  2006-01       Impact factor: 31.743

4.  CDK-independent activation of estrogen receptor by cyclin D1.

Authors:  R M Zwijsen; E Wientjens; R Klompmaker; J van der Sman; R Bernards; R J Michalides
Journal:  Cell       Date:  1997-02-07       Impact factor: 41.582

5.  Cyclin D1 and D3 associate with the SCF complex and are coordinately elevated in breast cancer.

Authors:  A Russell; M A Thompson; J Hendley; L Trute; J Armes; D Germain
Journal:  Oncogene       Date:  1999-03-18       Impact factor: 9.867

Review 6.  Cell cycle in mouse development.

Authors:  Maria A Ciemerych; Peter Sicinski
Journal:  Oncogene       Date:  2005-04-18       Impact factor: 9.867

7.  Prolactin potentiates transforming growth factor alpha induction of mammary neoplasia in transgenic mice.

Authors:  Lisa M Arendt; Teresa A Rose-Hellekant; Eric P Sandgren; Linda A Schuler
Journal:  Am J Pathol       Date:  2006-04       Impact factor: 4.307

Review 8.  Cyclin D1 in breast cancer.

Authors:  D M Barnes; C E Gillett
Journal:  Breast Cancer Res Treat       Date:  1998       Impact factor: 4.872

Review 9.  Minireview: Cyclin D1: normal and abnormal functions.

Authors:  Maofu Fu; Chenguang Wang; Zhiping Li; Toshiyuki Sakamaki; Richard G Pestell
Journal:  Endocrinology       Date:  2004-08-26       Impact factor: 4.736

10.  Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization.

Authors:  J A Diehl; M Cheng; M F Roussel; C J Sherr
Journal:  Genes Dev       Date:  1998-11-15       Impact factor: 11.361

View more
  6 in total

Review 1.  Immunomodulatory effects of sex hormones: requirements for pregnancy and relevance in melanoma.

Authors:  Elizabeth Ann L Enninga; Shernan G Holtan; Douglas J Creedon; Roxana S Dronca; Wendy K Nevala; Simona Ognjanovic; Svetomir N Markovic
Journal:  Mayo Clin Proc       Date:  2014-04       Impact factor: 7.616

2.  Modeling prolactin actions in breast cancer in vivo: insights from the NRL-PRL mouse.

Authors:  Kathleen A O'Leary; Michael P Shea; Linda A Schuler
Journal:  Adv Exp Med Biol       Date:  2015       Impact factor: 2.622

3.  Prolactin cooperates with loss of p53 to promote claudin-low mammary carcinomas.

Authors:  K A O'Leary; D E Rugowski; R Sullivan; L A Schuler
Journal:  Oncogene       Date:  2013-07-22       Impact factor: 9.867

Review 4.  D-type Cyclins are important downstream effectors of cytokine signaling that regulate the proliferation of normal and neoplastic mammary epithelial cells.

Authors:  Qian Zhang; Kazuhito Sakamoto; Kay-Uwe Wagner
Journal:  Mol Cell Endocrinol       Date:  2013-04-04       Impact factor: 4.102

5.  Prospecting major genes in dairy buffaloes.

Authors:  G M F de Camargo; R R Aspilcueta-Borquis; M R S Fortes; R Porto-Neto; D F Cardoso; D J A Santos; S A Lehnert; A Reverter; S S Moore; H Tonhati
Journal:  BMC Genomics       Date:  2015-10-28       Impact factor: 3.969

6.  Involvement of miR-106b in tumorigenic actions of both prolactin and estradiol.

Authors:  Kuan-Hui Ethan Chen; Karissa Bustamante; Vi Nguyen; Ameae M Walker
Journal:  Oncotarget       Date:  2017-05-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.